The US Food and Drug Administration (FDA) has approved a subcutaneous autoinjector version of Saphnelo (anifrolumab) for adult patients suffering from systemic lupus erythematosus (SLE). This newly cleared Saphnelo Pen offers enhanced flexibility and convenience, transitioning treatment from clinical infusion settings to weekly self-administration by the patient.
The FDA’s decision was supported by findings from the Phase III TULIP-SC clinical trial, which demonstrated a statistically significant reduction in disease activity compared to a placebo in patients with moderate to severe SLE. The safety profile of this subcutaneous formulation remained consistent with the previously established intravenous version. As a first-in-class therapy, Saphnelo works by targeting the type I interferon pathway, a major driver of the inflammation and immune responses characteristic of lupus.
Systemic lupus erythematosus is a chronic autoimmune condition that can impact multiple organ systems, often resulting in long-term complications, fatigue, and joint pain. The introduction of the autoinjector format is expected to improve patient adherence and quality of life by providing a more accessible treatment option. Beyond the United States, the subcutaneous formulation has already gained regulatory approval in the European Union and Japan, with ongoing reviews in several other global markets.